Loading...
NPI 1932260700 · London, KY · Long Term Care Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laurel Housing Inc is a long term care pharmacy provider located in London, Kentucky. This profile covers 8 Medicare and 14 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laurel Housing Inc |
| Address | 208 W 12th St |
| City | London |
| State | KY |
| ZIP | 40741 |
| Taxonomy | Long Term Care Pharmacy |
| NPI Enumerated | December 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $26.5K |
| Medicaid | $0 |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 130 | $70 | $9K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 60 | $140 | $8.2K |
| G0008 | Administration of influenza virus vaccine | 130 | $30 | $3.8K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 60 | $40 | $2.2K |
| 90732 | The provider intramuscularly or subcutaneously injects pneumococcal polysaccharide vaccine in an individual two years or older. This vaccine provides protection against meningitis and pneumonia that… | 20 | $130 | $2.1K |
| 0134A | N/A | 30 | $40 | $950 |
| G0009 | Administration of pneumococcal vaccine | 20 | $30 | $460 |
| 91313 | N/A | 30 | $0 | $0 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 8 CPT/HCPCS codes.
View: State1 / 2
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
14 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0003A | N/A | 20 | $0 | $0 |
| 0064A | N/A | 70 | $0 | $0 |
| 0134A | N/A | 50 | $0 | $0 |
| 888888 | N/A | 20 | $0 | $0 |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 80 | $0 | $0 |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 70 | $0 | $0 |
| 90673 | This code represents a trivalent flu vaccine that protects against three strains of influenza. It is made using recombinant DNA technology and includes only a specific protein from the virus. The… | 50 | $0 | $0 |
| 90682 | This code represents a quadrivalent flu vaccine given by injection into the muscle. The vaccine is made using recombinant DNA technology and contains only a protein from the virus. It does not… | 110 | $0 | $0 |
| 90684 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 21–valent vaccine, protecting against 21 strains of the… | 10 | $0 | $0 |
| 91313 | N/A | 50 | $0 | $0 |
Showing 1–10 of 14
How this provider's Medicaid billing volume and revenue compare to other Kentucky providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Kentucky median
14 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0009 | Administration of pneumococcal vaccine | 7 | 10 | 20 | $10 | $3.8K |
| 90682 | This code represents a quadrivalent flu vaccine given by injection into the muscle. The vaccine is made using recombinant DNA technology and contains only a protein from the virus. It does not… | 8 | 40 | 30 | $30 | $3.7K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 10 | 40 | 30 | $40 | $3.2K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 12 | 20 | 30 | $80 | $2.6K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 21 | 60 | 30 | $20 | $2.6K |
| 90673 | This code represents a trivalent flu vaccine that protects against three strains of influenza. It is made using recombinant DNA technology and includes only a specific protein from the virus. The… | 3 | 10 | 50 | $30 | $2.5K |
| 0003A | N/A | 31 | 50 | 50 | $10 | $1.6K |
| 0064A | N/A | 30 | 120 | 40 | $20 | $1.1K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 13 | 50 | 20 | $10 | $620 |
| 0134A | N/A | 10 | 40 | 30 | $20 | $620 |
Showing 1–10 of 14
Other providers in the same ZIP code as Laurel Housing Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.